Yahoo Web Search

Search results

1. finance.yahoo.com › news › compared-estimates-unitedCompared to Estimates, United Therapeutics (UTHR) Q1 Earnings ...

   finance.yahoo.com › news › compared-estimates-united

   • Cached

   May 1, 2024 · Zacks Equity Research. Wed, May 1, 2024, 9:30 AM 2 min read. In this article: UTHR. United Therapeutics (UTHR) reported $677.7 million in revenue for the quarter ended March 2024,...

2. seekingalpha.com › article › 4623553-unitedUnited Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth ...

   seekingalpha.com › article › 4623553-united

   Aug 3, 2023 · This equates to a fair forward P/E of 12.6x, and thus supports a buy rating in my view, suggesting UTHR is undervalued trading at just ~10x earnings, a 26% value gap to the upside. Conclusion

3. Videos

   • 

     13:24

     youtube.com

     Options Trading Explained - COMPLETE BEGINNERS GUIDE (Part 1)

     Jun 23, 2020

     3.9M Views

   • 

     8:08

     youtube.com

     How To Use ATR To Maximize Gains | Day Trading Strategy

     Oct 7, 2021

     7.4K Views

   • 

     5:35

     youtube.com

     Calculate the Present Value for Multiple Cash Flows (Intermediate Accounting I #3)

     Jul 7, 2014

     141.9K Views

   View all

4. www.zacks.com › stock › newsUnited Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives ...

   www.zacks.com › stock › news

   • Cached

   May 2, 2024 · United Therapeutics ‘ (. UTHR Quick Quote. UTHR - Free Report) first-quarter 2024 earnings of $6.17 per share beat the Zacks Consensus Estimate of $5.63. Earnings rose 27% year over year on the ...

5. www.fool.com › quote › nasdaqUnited Therapeutics (NASDAQ: UTHR) - The Motley Fool

   www.fool.com › quote › nasdaq

   • Cached

   United Therapeutics (NASDAQ: UTHR) $264.27. (-0.7%) -$1.78. Price as of May 10, 2024, 4:00 p.m. ET. Key Data Points. Current Price. $264.27. Daily Change. (-0.7%) -$1.78. Day's Range. $263.93...

   • Works For: United Therapeutics

6. People also ask

   Is UTHR a good stock to buy?

   • You can see through the FY'22 bear market UTHR caught a heavy bid, in line with its resiliency premium, and economic drivers of shareholder value. The last 3-months have been incredibly important in this regard, having bounced from the key support of $200. It found buyers at this range back in FY'22, then rallied some $70/share at the peak.

   United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More T…

   seekingalpha.com/article/4623553-united-therapeutics-eyeing-a-re-rating-to-12-13x-pe-growth-more-than-justified

   See all results for this question

   Should you buy United Therapeutics Corporation (UTHR)?

   • United Therapeutics Corporation (NASDAQ: UTHR) reported strong quarterly results, adding strength to its economic characteristics. The company's financial performance and cash flows indicate the potential for sustained high returns on operating capital employed. I am eyeing $273/share, or 12.6x forward P/E by FY'23 yearend. Net-net, reiterate buy.

   United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More T…

   seekingalpha.com/article/4623553-united-therapeutics-eyeing-a-re-rating-to-12-13x-pe-growth-more-than-justified

   See all results for this question

   Who is United Therapeutics Corporation (UTHR)?

   • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. UTHR passed our risk checks.

   United Therapeutics (Nasdaq:UTHR) - Stock Price, News & Analysis - …

   simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics

   See all results for this question

   Is UTHR undervalued?

   • This is significant, because UTHR in my eyes is undervalued given the market pays just 61% higher market value than 3-years ago, but I've got the firm having compounded its intrinsic value by ~98% over this time [Note: Compounding growth rates, Figure 6, above]. Figure 7.

   United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More T…

   seekingalpha.com/article/4623553-united-therapeutics-eyeing-a-re-rating-to-12-13x-pe-growth-more-than-justified

   See all results for this question

7. www.zacks.com › stock › newsUnited Therapeutics (UTHR) Q4 Earnings: How Key Metrics ...

   www.zacks.com › stock › news

   • Cached

   Feb 21, 2024 · UTHR - Free Report) reported revenue of $614.7 million, up 25.1% over the same period last year. EPS came in at $4.36, compared to $2.67 in the year-ago quarter. The reported revenue compares to...

8. finance.yahoo.com › news › united-therapeutics-uthrUnited Therapeutics (UTHR) Q4 Earnings: How Key Metrics ...

   finance.yahoo.com › news › united-therapeutics-uthr

   • Cached

   Feb 21, 2024 · In this article: UTHR. For the quarter ended December 2023, United Therapeutics (UTHR) reported revenue of $614.7 million, up 25.1% over the same period last year. EPS came in at $4.36,...

9. simplywall.st › nasdaq-uthr › united-therapeuticsUnited Therapeutics (Nasdaq:UTHR) - Stock Price, News ...

   simplywall.st › nasdaq-uthr › united-therapeutics

   • Cached

   May 5, 2024 · Is UTHR's price volatile compared to industry and market? UTHR volatility; UTHR Average Weekly Movement: 4.4%: Biotechs Industry Average Movement: 11.6%: Market Average Movement: 6.1%: 10% most volatile stocks in US Market: 16.7%: 10% least volatile stocks in US Market: 3.0%